Unlock Global Insights – Save 20% on Market Reports with Code ONLINE20
What Is The Global Market Value Of The Diabetic Foot Ulcer Biologics Industry In 2025?
The diabetic foot ulcer biologics market size has shown significant growth in recent years. It is projected to expand from $1.78 billion in 2024 to $1.93 billion in 2025, achieving a compound annual growth rate (CAGR) of 8.5%. This historical development can be ascribed to an increasing diabetic population, a rising incidence of chronic wounds, a growing demand for advanced wound care, the expansion of hospital infrastructure, and heightened clinical awareness of biologics.
The market for diabetic foot ulcer biologics is projected to experience substantial expansion in the coming years. This market is anticipated to reach $2.65 billion by 2029, exhibiting a compound annual growth rate (CAGR) of 8.3%. Factors driving this growth over the projected period include increased investment in regenerative medicine, an expanding elderly population prone to slower healing, enhanced accessibility of reimbursement programs, an increase in clinical trials for biologic treatments, and a greater emphasis on limb preservation therapies. Key developments expected during this forecast timeframe encompass progress in biologic wound healing technologies, ongoing breakthroughs in stem cell therapy, the creation of tissue-engineered skin substitutes, intensive research and development into extracellular matrix products, and the advent of 3D bioprinting for chronic wound management.
Unlock Your Free Sample Report for Exclusive Market Data:
https://www.thebusinessresearchcompany.com/sample.aspx?id=25751&type=smp
What Are The Drivers Pushing New Developments In The Diabetic Foot Ulcer Biologics Market?
The increasing incidence of diabetes is anticipated to fuel the expansion of the diabetic foot ulcer biologics market in the future. Diabetes, a chronic medical condition, is characterized by elevated blood glucose levels resulting from the body’s inability to produce or effectively use insulin. The growing occurrence of diabetes stems from inactive lifestyles, which, in turn, boosts the need for enduring care options that efficiently regulate blood sugar while causing minimal interference to daily life. These diabetic foot ulcer biologics are crucial in diabetes management because they hasten wound recovery, avert infections, and mitigate complications arising from persistent foot ulcers. For example, data from the International Diabetes Federation (IDF) Atlas, a Belgium-based non-profit organization, indicated that in 2024, 9.5 million of the 589 million adults with diabetes had type 1 diabetes, a figure projected to increase to 853 million by 2050. This information was released in April 2025. Consequently, the expanding prevalence of diabetes is a significant catalyst for the growth of the diabetic foot ulcer biologics market.
What Are The Major Segment Types Covered In The Diabetic Foot Ulcer Biologics Market?
The diabetic foot ulcer biologics market covered in this report is segmented –
1) By Type: Growth Factors, Skin Substitutes, Collagen-Based Biologics, Cell-Based Biologics
2) By Indication: Neuro-Ischemic Ulcers, Neuropathic Diabetic Foot Ulcer, Ischemic Diabetic Foot Ulcer
3) By Technology: Gene Therapy, Stem Cell Therapy, Tissue Engineering
4) By End User: Hospitals, Clinics, Ambulatory Surgical Centers, Long-Term Care Settings, Other End Users
Subsegments:
1) By Growth Factors: Platelet-Derived Growth Factor, Epidermal Growth Factor, Fibroblast Growth Factor, Vascular Endothelial Growth Factor
2) By Skin Substitutes: Synthetic Skin Substitutes, Biological Skin Substitutes, Composite Skin Substitutes
3) By Collagen-Based Biologics: Bovine-Derived Collagen, Porcine-Derived Collagen, Human-Derived Collagen
4) By Cell-Based Biologics: Autologous Cell-Based Biologics, Allogeneic Cell-Based Biologics, Stem Cell-Based Biologics
Which Trends Are Impacting The Diabetic Foot Ulcer Biologics Market?
Companies operating in the diabetic foot ulcer biologics market are intensifying their focus on research and development in biologic therapies, such as placental-derived allograft, to improve wound healing, minimize complications, and enhance patient outcomes in treating chronic foot ulcers. Placental-derived allograft is a biological tissue graft derived from donated human placental tissues, specifically the amnion or chorion, and is utilized in medical applications to encourage healing, decrease inflammation, and support tissue regeneration. For example, in January 2025, BioStem Technologies Inc., a US-based pharmaceutical company, initiated a clinical trial leveraging its BioREtain technology with Vendaje for the treatment of diabetic foot ulcers. This study aims to demonstrate the effectiveness of Vendaje combined with standard care versus standard care alone in healing non-healing diabetic foot ulcers. A follow-up phase is included to evaluate the long-term durability and stability of healed wounds, ensuring sustained treatment success and reducing the likelihood of ulcer recurrence.
Which Key Market Players Are Investing In Expansion And Innovation Of Diabetic Foot Ulcer Biologics Market?
Major companies operating in the diabetic foot ulcer biologics market are Johnson & Johnson, Zimmer Biomet Holdings Inc., Smith & Nephew plc, Integra LifeSciences Holdings Corp., Gunze Ltd., Organogenesis Holdings Inc., MIMEDX Group Inc., LifeNet Health, Bharat Biotech, BioTissue Holdings Inc., Aroa Biosurgery, Tissue Regenix Group plc, Stempeutics Research, Energenesis Biomedical Co. Ltd., Human Biosciences Inc., Helixmith Co. Ltd., ACell Inc., Anterogen Co. Ltd., Lavior Pharma Inc., Technophage SA
Download The Full Report For Exclusive Market Findings:
https://www.thebusinessresearchcompany.com/report/diabetic-foot-ulcer-biologics-global-market-report
What Are The Regional Market Dynamics Impacting The Diabetic Foot Ulcer Biologics Industry?
North America was the largest region in the diabetic foot ulcer biologics market in 2024. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the diabetic foot ulcer biologics market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.
Request A Customized Version Of The Diabetic Foot Ulcer Biologics Market Report:
https://www.thebusinessresearchcompany.com/customise?id=25751&type=smp
Browse Through More Reports Similar to the Global Diabetic Foot Ulcer Biologics Market 2025, By The Business Research Company
Diabetic Foot Ulcer Global Market Report 2025
https://www.thebusinessresearchcompany.com/report/diabetic-foot-ulcer-global-market-report
Diabetic Foot Ulcer Treatment Global Market Report 2025
https://www.thebusinessresearchcompany.com/report/diabetic-foot-ulcer-treatment-global-market-report
Diabetic Footwear Global Market Report 2025
https://www.thebusinessresearchcompany.com/report/diabetic-footwear-global-market-report
Get in touch with us:
The Business Research Company: https://www.thebusinessresearchcompany.com/
Americas +1 310-496-7795
Asia +44 7882 955267 & +91 8897263534
Europe +44 7882 955267
Email us at info@tbrc.info
Follow us on:
LinkedIn: https://in.linkedin.com/company/the-business-research-company
YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ
Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model